1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

08 May 2024
Admin
News Article

VYNE Therapeutics Receives FDA Clearance for IND Application of VYN202

VYNE Therapeutics Receives FDA Clearance for IND Application of VYN202, a Unique BD2-Selective BET Inhibitor

Overview

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced today that the U.S. Food and Drug Administration has cleared its Investigational New Drug application (IND) for VYN202, an oral BD2-selective BET inhibitor. This marks a significant advancement in the company's efforts to develop therapies for autoimmune diseases. David Domzalski, President and CEO of VYNE, expressed excitement about the potential of VYN202 as a treatment option.

Phase 1a Trial

The company plans to initiate a Phase 1a trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VYN202 in healthy volunteers.
This trial will include single ascending dose/multiple ascending dose (SAD/MAD) components and is expected to enroll approximately 64 subjects.
Pending successful completion of Phase 1a, VYNE intends to move forward with Phase 1b trials targeting moderate-to-severe plaque psoriasis and adult-onset rheumatoid arthritis, with results anticipated in the latter half of 2025.

VYN202

VYN202 is an oral small molecule BD2-selective BET inhibitor designed to offer high selectivity, potency, and oral bioavailability.
It differs structurally from VYNE's pan-BET inhibitor, VYN201, and is covered by distinct patent applications.

BET Proteins

BET proteins play a crucial role in gene transcription regulation through epigenetic interactions, particularly in modulating B and T cell activation and inflammation.
BET inhibitors hold promise for addressing various immuno-inflammatory and fibrotic diseases by blocking pro-inflammatory cytokine transcription, with potential applications in myeloproliferative neoplastic disorders.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!